GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Loans Receivable

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Loans Receivable : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Loans Receivable?

TC BioPharm (Holdings)'s Loans Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.


TC BioPharm (Holdings) Loans Receivable Historical Data

The historical data trend for TC BioPharm (Holdings)'s Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Loans Receivable Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
- - - - -

TC BioPharm (Holdings) Quarterly Data
Dec19 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TC BioPharm (Holdings) Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


TC BioPharm (Holdings) Loans Receivable Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Traded in Other Exchanges
Address
Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.
Executives
Renaissance Capital Partners Ltd 10 percent owner 42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD